🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Bausch Health Americas clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and India registers with Bausch Health Americas as lead sponsor. Synced 26 Sep 2026
13Current trials
6Recruiting now
5Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Bausch Health Americas is the lead sponsor of 13 current clinical trials in our USA, UK and India registers. 6 are recruiting patients now. The most common phase is Phase 4. The drugs named most often in its trials are Brodalumab, Rifaximin SSD and Budesonide. The most-studied condition is Psoriasis.

ClinicalTrials.gov trials by status

  • Recruiting646%
  • Active, closed646%
  • By invitation18%

Trials by phase

  • Phase 4538%
  • Phase 3323%
  • Not applicable215%
  • Observational215%
  • Phase 218%
01

Clinical trials sponsored by Bausch Health Americas

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
NCT04314375 · Ulcerative Colitis
Phase 4 Recruiting 2023-09 USA
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
NCT07524946 · ClinicalTrials.gov ↗ · Acne Vulgaris
Phase 4 Recruiting 2026-04 USA
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03987763 · ClinicalTrials.gov ↗ · Psoriasis
Phase 4 Recruiting 2019-10 USA
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
NCT07187297 · ClinicalTrials.gov ↗ · Wrinkle, Lax Skin, Lines Skin
Not applicable Recruiting 2025-10 USA
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785 · ClinicalTrials.gov ↗ · Diarrhea, Gastroenteritis, Bacterial Infection
Drug: Rifaximin
Phase 4 Recruiting 2026-02 USA
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
NCT07428538 · ClinicalTrials.gov ↗ · Hepatitis
Phase 3 Recruiting 2026-01 USA
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
NCT03254667 · ClinicalTrials.gov ↗ · Psoriasis
Observational By invitation 2017-07 USA
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
NCT05297448 · ClinicalTrials.gov ↗ · Hepatic Encephalopathy
Phase 3 Active, closed 2022-08 UK, USA, India
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
NCT05071716 · ClinicalTrials.gov ↗ · Hepatic Encephalopathy
Phase 3 Active, closed 2022-04 USA
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
NCT07214272 · ClinicalTrials.gov ↗ · Skin Resurfacing
Not applicable Active, closed 2025-10 USA
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
NCT00568997 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Observational Active, closed 2005-06 USA
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
NCT07723924 · ClinicalTrials.gov ↗ · Functional Constipation (FC)
Phase 2 Active, closed 2026-06 USA
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03240809 · ClinicalTrials.gov ↗ · Psoriasis
Phase 4 Active, closed 2020-01 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Bausch Health Americas trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Bausch Health Americas trials

15 conditions
Psoriasis3Hepatic Encephalopathy2Ulcerative Colitis1Acne Vulgaris1Skin Resurfacing1Atopic Dermatitis1Wrinkle1Lax Skin1Lines Skin1Diarrhea1Gastroenteritis1Bacterial Infection1Acute Diarrhea1Hepatitis1Functional Constipation (FC)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA136
Clinical trials in UK10
Clinical trials in India10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Psoriasis

SponsorTrials
Jiangsu Hansoh Pharmaceutical2
Haisco Pharmaceutical Group2
InventisBio1
Ganzhou Hemay Pharmaceutical1
Shenzhen People's Hospital1

Sponsors with the most current trials registered for this condition.

06

Questions about Bausch Health Americas trials

How many clinical trials does Bausch Health Americas sponsor?

Bausch Health Americas is the lead sponsor of 13 current trials on ClinicalTrials.gov in our USA, UK and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Bausch Health Americas trials recruiting?

Yes. 6 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Bausch Health Americas testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Brodalumab (2), Rifaximin SSD (2), Budesonide (1), Pimecrolimus (1) and Rifaximin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.